The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience. Abstract #1294

Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Aim(s): evaluation efficacy and toxicity
Materials and methods: All pts received long acting somatostatin analogs.The mean age was 55 years, 4 male, 15 female. The most of pts had pancreatic neuroendocrine tumor – 16(84%)pts, kidney NET–1 pt,primary multiple synchronous panceatic+kidney had 2 patients.There was index proliferation Ki67% determination: Ki67 less 3% -1 pt, Ki67%= 3-20% had 15pts; ki67% more than 20% had 2pts. There were 3 pts with G1 NETs, 16 patients with G2 NETs.Cytoreductive surgery was performed in 9 -47,3%pts. 6/19 pts had 0-1-2 prior lines of CT and 13/19 patients were heavily pretreated with more than 3 lines of CT. Previous treatment included interferon α, octreotide LAR, XelOx, EP and of temozolomide, paclitaxel and fluoropyrimidines, everolimus. Sunitinib as a first line treatment was in 3 patients, after everolimus therapy was in 2 cases.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova
#1702 Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S).
Introduction: Two targeted compounds are validated for treatment of pNETs – E and S.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Vera Gorbunova